Anton Lindqvist - Diamyd Medical Chief Officer

DMN Stock  EUR 1.45  0.01  0.68%   

Insider

Anton Lindqvist is Chief Officer of Diamyd Medical AB
Age 43
Phone46 86 61 00 26
Webhttps://www.diamyd.com

Diamyd Medical Management Efficiency

The company has return on total asset (ROA) of (0.2531) % which means that it has lost $0.2531 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4155) %, meaning that it generated substantial loss on money invested by shareholders. Diamyd Medical's management efficiency ratios could be used to measure how well Diamyd Medical manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

INSIDER Age

Raymond KummerCogent Communications Holdings
74
Holger Hommesecotel communication ag
46
Britta SchulzLPKF Laser Electronics
50
Michael AgaterLPKF Laser Electronics
N/A
Markus Hendrichecotel communication ag
43
Ping ChengDelta Electronics Public
61
Achim Theisecotel communication ag
59
ChinMing ChenDelta Electronics Public
53
Simon ReiserLPKF Laser Electronics
N/A
Nipaporn JiarajareevongDelta Electronics Public
N/A
Klaus FiedlerLPKF Laser Electronics
52
Throsten Renzierecotel communication ag
N/A
Jrgen BergedieckLPKF Laser Electronics
N/A
Peter Zilsecotel communication ag
60
Oliver Jansenecotel communication ag
55
Tzushing KoDelta Electronics Public
75
Wilfried Kallenbergecotel communication ag
63
David SchaefferCogent Communications Holdings
67
JeanMichel SlagmuylderCogent Communications Holdings
60
Stephan SchmidtLPKF Laser Electronics
N/A
Vichai SaksuriyaDelta Electronics Public
61
Diamyd Medical AB , a diabetes company, engages in the development of combination therapies for the treatment of autoimmune diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB in April 2013. DIAMYD MEDICAL operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 6 people. Diamyd Medical AB (DMN) is traded on Frankfurt Exchange in Germany and employs 20 people.

Management Performance

Diamyd Medical AB Leadership Team

Elected by the shareholders, the Diamyd Medical's board of directors comprises two types of representatives: Diamyd Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Diamyd. The board's role is to monitor Diamyd Medical's management team and ensure that shareholders' interests are well served. Diamyd Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Diamyd Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ulf MBA, CEO Pres
Anton Lindqvist, Chief Officer
Martina Widman, Chief Officer
Anna BSc, Chief Officer
Christoph Nowak, Chief Officer
Eva Karlstrom, Chief Officer

Diamyd Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Diamyd Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in Diamyd Stock

Diamyd Medical financial ratios help investors to determine whether Diamyd Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diamyd with respect to the benefits of owning Diamyd Medical security.